Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half ...

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - - Marketing Authorization Application (MAA) for veligrotug for TED submitted to the European Medicines Agency (EMA) in January 2026 - - Phase 3 topline data readout for subcutaneous elegrobart (VRDN-003) REVEAL-1 and REVEAL-2 ...

SHENANDOAH TELECOMMUNICATIONS COMPANY UNITED STATES OF AMERICA SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) Commission File No.: 000-09881 (Exact name of registrant as specified in its charter) Virginia 54-1162807 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 500 Shentel Way, Edinburg, Virginia 22824 (Address of principal executive offices) (Zip Code) (540) 984-4141 (Registrant's telephone number, including area code) S ...

Exhibit 99.1 C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Bioge ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40969 ENTRADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-3983399 (State ...

Exhibit 99.1 The J.M. Smucker Co. Announces Fiscal 2026 Third Quarter Results ORRVILLE, Ohio, Feb. 26, 2026 /PRNewswire/ -- The J.M. Smucker Co. (NYSE: SJM) today announced results for the third quarter ended January 31, 2026, of its 2026 fiscal year. Financial results for the third quarter of fiscal year 2026 reflect the divestiture of certain Sweet Baked Snacks value brands on March 3, 2025, and the divestiture of the Voortman business on December 2, 2024. All comparisons are to the third quarter of the p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 0-49677 WEST BANCORPORATION, INC. (Exact name of registrant as specified in its charter) Iowa 42-1230603 (State or ...

Financial Performance - Fourth quarter net revenue was $1.29 billion, a decrease of 13.4% year-over-year, primarily due to lower political advertising revenue[1] - The company reported a net loss of $170 million for Q4, an increase of 174.2% compared to the prior year, with a net income margin of (13.2%)[10] - Adjusted EBITDA for Q4 was $433 million, down 31.1% year-over-year, with an adjusted EBITDA margin of 33.6%[10] - Nexstar Media Group reported net revenue of $1,289 million for Q4 2025, a decrease of 13.3% compared to $1,488 million in Q4 2024[29] - The company experienced a net loss of $170 million in Q4 2025, compared to a net income of $229 million in Q4 2024, reflecting a significant decline[29] - Adjusted EBITDA for the year ended December 31, 2025, was $1,561 million, down from $2,004 million in 2024, representing a decline of 22.0%[34] Revenue Breakdown - Distribution revenue for Q4 was $720 million, up 0.8% from the previous year, while advertising revenue fell to $549 million, down 27.6%[7] - Adjusted Free Cash Flow for the year ended December 31, 2025, was $829 million, down from $1,203 million in 2024, indicating a decrease of 31.1%[39] - Total operating expenses for the year ended December 31, 2025, were $4,100 million, slightly lower than $4,139 million in 2024[29] Cash Flow and Debt - Net cash provided by operating activities in Q4 was $190 million, a decrease of 53.8% year-over-year[10] - Cash flows from operating activities for the year ended December 31, 2025, were $891 million, down from $1,250 million in 2024[31] - As of December 31, 2025, total debt was $6.33 billion, down from $6.52 billion in the previous year[17] - Cash and cash equivalents at the end of Q4 2025 were $280 million, an increase from $144 million at the end of Q4 2024[31] Shareholder Returns - The company returned $351 million to shareholders in 2025, representing 42% of adjusted free cash flow[7] - The company reported a basic net loss per share of $5.63 for Q4 2025, compared to earnings of $7.68 per share in Q4 2024[29] - Nexstar Media Group's weighted average number of common shares outstanding decreased from 32,311 thousand in 2024 to 30,349 thousand in 2025[29] Strategic Initiatives - The proposed acquisition of TEGNA Inc. is valued at $6.2 billion and is expected to close in the second half of 2026, subject to regulatory approvals[7] - The CW network achieved a 19% total audience growth compared to the prior year, ranking as the tenth largest and second fastest growing ad-supported network overall[7] - The company recorded a $381 million impairment on its investment in TV Food Network in Q4 2025, impacting overall financial performance[35]

Exhibit 99.1 TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today, Thursday, February 26, 2026, at 8:30 AM ET New York, NY, (February 26, 2026) – TG Therapeutics, In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2025 Or ZAI LAB LIMITED (Exact Name of Registrant as Specified in its Charter) __________________________ Cayman Islands 98-1144595 (State or Other Jurisdiction of Incorporation or Organization) 899 Halei Road Building B, Pudong Shanghai ...